Multinationals abuse Korea's patent trial system

Pfizer Korea and Sanofi-Aventis Korea have sought to prevent the insurance prices of their original medicine from being decreased by 20 percent, when a generic drug gets listed for insurance coverage, through a trial to confirm the scope of patent rights over generic products, indicating they are abusing the nation's patent trial system.

Under the new system, when the patent period of an ori...